(Q37532799)

20 August 2017

1 reference

title

Influenza control in the 21st century: Optimizing protection of older adults (English)

1 reference

20 August 2017

1

Arnold S Monto

1 reference

20 August 2017

4

Janet E McElhaney

1 reference

20 August 2017

2

Filippo Ansaldi

1 reference

20 August 2017

Richard Aspinall

3

1 reference

20 August 2017

Luis F Montaño

5

1 reference

20 August 2017

Kristin L Nichol

6

1 reference

20 August 2017

Joan Puig-Barberà

7

1 reference

20 August 2017

Joe Schmitt

8

1 reference

20 August 2017

Iain Stephenson

9

1 reference

20 August 2017

language of work or name

English

0 references

publication date

24 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

27

1 reference

20 August 2017

issue

37

1 reference

20 August 2017

page(s)

5043-5053

1 reference

Impact of influenza on mortality in relation to age and underlying disease, 1967-1989.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza-associated hospitalizations in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The unmet need in the elderly: designing new influenza vaccines for older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccines. A reappraisal of their use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Immunogenicity and protective efficacy of influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Real-time monitoring of the influenza vaccine field effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccine: the challenge of antigenic drift.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccine--outmaneuvering antigenic shift and drift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Factors influencing uptake of influenza vaccination among hospital-based health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Epidemiology and unique aspects of aging and infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza deaths in Leicestershire during the 1989-90 epidemic: implications for prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

A study of the impact of influenza on the functional status of frail older people.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

A new paradigm for clinical investigation of infectious syndromes in older adults: assessment of functional status as a risk factor and outcome measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Respiratory syncytial virus infection in elderly and high-risk adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza and the winter increase in mortality in the United States, 1959-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza and its relationship to circulatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Economic evaluation of strategies for the control and management of influenza in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Could a federal program to promote influenza vaccination among elders be cost-effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

No immunity for the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

EMBRYOLOGICAL DEVELOPMENT OF THE IMMUNE MECHANISM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Challenges for vaccination in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The human thymic microenvironment: new approaches to functional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Thymic involution with ageing: obsolescence or good housekeeping?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Changes in thymic function with age and during the treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Molecular quantitation of thymic output in mice and the effect of IL-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

An IL-7 fusion protein that shows increased thymopoietic ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evolutionary changes in influenza B are not primarily governed by antibody selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Mapping the antigenic and genetic evolution of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Comparison of three different influenza vaccines in institutionalised elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Response to influenza vaccine in people with non-protective HI antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Clinical experience with inactivated, virosomal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The virosome concept for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Approaches to improved influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Epidermal DNA vaccine for influenza is immunogenic in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Alphavirus-based expression vectors: strategies and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Antibody responses after dose-sparing intradermal influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Dose sparing with intradermal injection of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Serum antibody responses after intradermal vaccination against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Prospects for universal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evaluation of a Neuraminidase-Specific Influenza A Virus Vaccine in Children: Antibody Responses and Effects on Two Successive Outbreaks of Natural Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.06.032

1 reference

20 August 2017

1 reference